Authors
Sisca Silvana, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia AND Department of Pediatrics, Faculty of Medicine, Universitas HKBP Nommensen, Medan, Indonesia.Follow
Iskandar Japardi, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, IndonesiaFollow
Muhammad Rusda, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
Rini Savitri Daulay, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
Agung Putra, Stem Cell and Cancer Research (SCCR), Faculty of Medicine, Universitas Islam Sultan Agung (Unissula), Semarang, Indonesia.Follow
Irawan Mangunatmadja, Department of Pediatrics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.Follow
Dewi Masyithah Darlan, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
Sri Sofyani, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
Yana Andreas, Faculty of Medicine, Universitas HKBP Nommensen, Medan, Indonesia.Follow
Abstract
Standard treatments for ischemic stroke are intravenous thrombolysis and endovascular recanalization. In the acute phase (
Keywords
CD31, VEGF, Secretome, MSC, Ischemic Stroke
How to Cite this Article
Silvana, Sisca; Japardi, Iskandar; Rusda, Muhammad; Daulay, Rini Savitri; Putra, Agung; Mangunatmadja, Irawan; Darlan, Dewi Masyithah; Sofyani, Sri; and Andreas, Yana
(2025)
"Mesenchymal Stem Cell Secretome for Ischemic Stroke: CD31 and VEGF Expression,"
Baghdad Science Journal: Vol. 22:
Iss.
4, Article 14.
DOI: https://doi.org/10.21123/bsj.2024.11813
DOWNLOADS
Since April 22, 2025
COinS